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Reply to the Editor:
We thank Drs Di Marco and Gerosa for con-
sidering that injection of mesenchymal stem
cells (MSCs) in decellularized scaffolds be-
fore in vivo implantation represents an inno-
vative concept in the valvular field, and we
completely agree that this concept requires
a careful validation. However, they ex-
pressed some concern about our conclusion
that bone marrow–derived mononuclear cell
injection induced a structural deterioration
of the scaffold and that MSCs induced a pro-
tective effect.
We believe that the observation of a del-
eterious effect of bone marrow–derived
mononuclear cells is an interesting point
because these cells had never been tested
in the field of valve tissue engineering,
whereas they are currently used in clinical
assays in the field of myocardial failure.
Also, we agree that endothelialization and
scaffold recolonization are 2 distinct pro-
cesses that do not always take place
together. However, Bertiplaglia and col-
leagues1 have demonstrated that 2 weeks
after in vitro interstitial cell seeding into
decellularized leaflets, grafted cells were
found penetrating the decellularized scaf-
fold and expressed various immunologic
differentiation patterns, such as fibroblasts,
myofibroblasts, smooth muscle cells, and
also endothelial cells. Similarly, we observed
a significant recolonization after injection of
MSCs, and moreover, as stated in our arti-
cle, pulmonary leaflets exhibited a typical
organization in 3 layers (ie, fibrosa, spon-
giosa, and ventricularis) in each animal of
the MSC group.2
Finally, several lines of evidence indi-
cate that in vivo recellularization of valve
scaffolds is no longer a ‘‘nonvalidated
route.’’ In a previous work we demon-
strated evidence of spontaneous recellulari-
zation of a decellularized valve.3 Such
results were emphasized by Dohmen and
coworkers4 comparing in vitro seeded and
nonseeded valves implanted in sheep. After
6 months, valves from both groups ex-
hibited full recolonization of the leaflets,
with comparable hemodynamic behavior
and valve remodeling.
We recognize that further studies are
needed to compare spontaneous recoloniza-
tion of an appropriated scaffold and the ef-
fects of in situ injection of autologous cells.
Also, we have to investigate how injected
autologous MSCs improve in situ recoloni-
zation by myofibroblasts and endothelial
cells or improve host cell migration. How-
ever, the challenge seems now to understand
and to favor in vivo, rather than in vitro,
valve scaffold recolonization.
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Letters to the Editor
The Journal of Thoracic and CardiovasculPercutaneous aortic valve
replacement with the CoreValve
bioprosthesis
To the Editor:
We read with interest the recent article by
Marcheix and colleagues1 in the Journal
dealing with percutaneous aortic valve im-
plantation. They reported their experience
using the second generation (21F) of the
CoreValve prosthesis (CoreValve, Inc, Paris,
France) in 10 consecutive high-risk surgical
patients (median logistic EuroSCORE of
32%). The prosthesis was successfully deliv-
ered in all cases, with a doubling of the aortic
valve area (from 0.57 6 0.19 to 1.2 6 0.35
cm2) and a significant decrease in transvalv-
ular gradient.
We would like to comment on these re-
sults and also ask for some clarifications
regarding their data:
Prosthesis sizing is an important issue.
On one hand, undersizing may be responsi-
ble for valve migration (owing to poor
anchoring), perivalvular leak, or patient–
prosthesis mismatch. On the other hand,
oversizing may theoretically lead to coro-
nary obstruction or favor atrioventricular
block. There is actually only one available
size of the CoreValve prosthesis, with
a 21-mm bioprosthesis implanted within
the stent frame. This valve is at the present
time indicated when the aortic annulus
diameter ranges from 20 to 27 mm.2 Al-
though the authors did not report the annu-
lus size in their group of patients, we do
not understand how proper sizing could be
achieved with a single-sized bioprosthesis.
Aortic bicuspidy is observed in half of
cases of severe aortic stenosis.3 In our expe-
rience, misdeployment of a valved stent is
likely to occur within a bicuspid aortic
valve,4,5 which may alter its long-term dura-
bility. Did the authors face a case with
a bicuspid aortic valve or have they system-
atically preoperatively screened the patients
and excluded for the endovascular proce-
dure those with a bicuspid aortic valve?ar Surgery c Volume 135, Number 6 1407
allow correct anchorage of the prosthesis
in the annulus.
All the patients had the echographic
aspect of a tricuspid aortic valve. We can-
not answer Zegdi and colleagues because
we do not have any experience with per-
cutaneous aortic valve implantation in
bicuspid valves. Bicuspid valves are gen-
erally more calcified than tricuspid valves
and frequently come with a moderate
dilatation of the aorta. They are less
favourable for currently used percutaneous
aortic valves.
Bertrand Marcheix, MD
Raymond Cartier, MD
Montreal, Quebec, Canada
doi:10.1016/j.jtcvs.2008.03.008
Does the method of lung
preservation influence outcome
after transplantation? An
analysis of 681 consecutive
procedures
To the Editor:
We read with great interest the study by Ga-
nesh and colleagues1 that compared various
graft preservation methods in lung trans-
plantation. The authors rigorously assessed
the association between the lung preserva-
tion method and the posttransplant survival
up to 3 years in a large cohort of patients;
they failed to detect any association. How-
ever, we think that the way the graft ische-
mic time was calculated and included in
the analysis may have biased the results.
Graft ischemic time has been shown to be
associated with survival after lung trans-
plantation in several studies.2,3 In these
studies, in case of double-lung transplanta-
tion, graft ischemic time was defined as
the time from donor crossclamping to reper-
fusion of the second lung. In their study, Ga-
nesh and colleagues considered ischemic
time as the time from donor crossclamping
This point is essential, because the efficacy
of different graft preservation solutions may
prove similar for short graft ischemic times
and different for longer ischemic times.
We think that the analysis of adjusted sur-
vival by preservation solution for patients
with a long ischemic time would have
yielded more insight in the efficacy of pres-
ervation solutions. However, the number of
patients in each group would have probably
been low, precluding powerful statistical
analysis. The authors report no interaction
between the graft ischemic time and the
preservation solution used; however, inter-
action testing is not powerful enough. We
agree that the way to definitely answer this
question is to conduct a randomized con-
trolled trial, and we think that such a trial
should stratify patients by the expected graft
ischemic time or the surgical procedure (sin-
gle vs bilateral lung transplantation).
Gabriel Thabut, MDa
Yves Castier, MDb
Herve´ Mal, MDa
Service de pneumologie B et transplantation
pulmonairea
Service de chirurgie thoracique et vasculaireb
Hoˆpital Bichat et Universite´ Paris 7,
Paris, France
References
1. Ganesh JS, Rogers CA, Banner NR,
Bonser RS. Does the method of lung preserva-
tion influence outcome after transplantation?
An analysis of 681 consecutive procedures. J
Thorac Cardiovasc Surg. 2007;134:1313-21.
2. Novick RJ, Bennett LE, Meyer DM,
Hosenpud JD. Influence of graft ischemic
time and donor age on survival after lung trans-
plantation. J Heart Lung Transplant. 1999;18:
425-31.
3. Thabut G, Mal H, Cerrina J, Dartevelle P,
Dromer C, Velly JF, et al. Graft ischemic
time and outcome of lung transplantation:
a multicenter analysis. Am J Respir Crit Care
Med. 2005;171:786-91.
Letters to the EditorAlthough this study summarizes an ini-
tial experience, we thank the authors for
sharing with us their results and for their
contribution to this important new field of
interventional therapy.
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We appreciate the authors’ concerns about
the quality of ourwork published the Journal
of Thoracic and Cardiovascular Surgery.
We totally agree with the two underlined
points and we would like to simply answer
the two questions.
It is true that prosthesis sizing is an
important issue. All the reported patients
had an aortic annulus diameter ranging
from 20 to 23 mm. Smaller and larger annuli
were considered as contraindicated so as to
to reperfusion of the first lung only. This
could lead to incorrect adjustment. Second,
we have found that the relationship between
graft ischemic time and survival could be of
exponential form, the graft ischemic time al-
tering the survival of recipients only when it
exceeds 4 to 6 hours.3 Unfortunately, the au-
thors did not report on the distribution of
graft ischemic time by the preservation
method. Given the incidence of local donors
in their cohort, we suspect that graft ische-
mic time was rather short in most patients.
doi:10.1016/j.jtcvs.2007.11.059
Reply to the Editor:
We appreciate the comments made by Tha-
but and colleagues on our article on lung
preservation.1 We agree that graft ischemia
time may be an important predictor to sur-
vival after lung transplantation, particularly
if this is particularly prolonged. The study
by Novick and colleagues2 did not find
any influence of graft ischemia time alone
on survival, but there was a significant
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